The platinum-based therapy of BRCA1 methylated triple negative breast cancer patients resulted in allelic loss of BRCA1 methylation, increased BRCA1 expression, and platinum resistance [25,26]. The gene discussed is BRCA1; the disease is triple-negative breast carcinoma.